Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12927434.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.
Medical subject headings
- Meningitis, Meningococcal
- Meningococcal Vaccines
- Nephrotic Syndrome
- Vaccination